Abstract
Objectives: Early mortality, defined as death within 120 days after initiated antitumor therapy, is an important issue especially for elder patients with B-cell lymphoma. This study aimed to evaluate the clinical value of comprehensive geriatric assessment (CGA) in early mortality prediction in elderly patients with B-cell lymphoma receiving immunochemotherapy. Methods: Seventy-six consecutive patients with newly diagnosed B-cell lymphoma receiving immunochemotherapy from a medical center in Taiwan were prospectively enrolled. Patients were divided into fit (n = 49) and frail (n = 27) groups per pretreatment CGA for early mortality comparison. Results: The early mortality rate in our patient cohort was 16% (n = 12): from 6% in patients with no CGA domain impairment to 43% in patients with ≥4 CGA domain impairment. The early mortality rate was 6% and 33% in fit and frail patients (odds ratio, 7.67; 95% CI, 1.86-31.6; P =.005), respectively. Frailty was the significant predictor for early mortality in univariate and multivariate analysis. Conclusion: In this study, the number of geriatric domain impairment is positively associated with the early mortality risk in elderly patients with B-cell lymphoma. Therefore, CGA can help clinicians to identify the risk of early mortality in elderly patients and provide alternative treatment.
Original language | English |
---|---|
Pages (from-to) | 399-407 |
Number of pages | 9 |
Journal | European Journal of Haematology |
Volume | 105 |
Issue number | 4 |
DOIs | |
State | Published - 01 10 2020 |
Bibliographical note
Publisher Copyright:© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Keywords
- early mortality
- frailty assessment
- non-Hodgkin lymphoma
- rituximab